New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA

Updated February 3rd, 2021

New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA

The FDA has approved PARP Inhibitor Olaparib for the treatment of advanced prostate cancer patients. Experts say this approval marks new personalized therapy options for specific tumors.

NOW
PLAYING
Remembering the Late Boxer Rubin 'Hurricane' Carter Who Died from Prostate Cancer After a Wrongful Conviction of Murder
NOW
PLAYING
New Hope For Stomach Cancer: Immunotherapy Drug Opdivo Now Approved As a First Treatment
NOW
PLAYING
Some Melanoma Survivors See Long-Term Side Effects After Immunotherapy, Says New Study
NOW
PLAYING
What's the Link Between Cancer and Vitamin D?
NOW
PLAYING
FDA Approves Lorlatinib to Treat Some Cases of Lung Cancer
NOW
PLAYING
Many Women Say They're Drinking More During Pandemic, 70% Don't Know Alcohol Increases Cancer Risk, According to SurvivorNet Survey
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.